NCT06829940 Efficacy of Baduanjin Exercise in COVID-19 Contraction Patients With Idiopathic Chronic Fatigue
| NCT ID | NCT06829940 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Chronic COVID-19 Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-10-09 |
| Primary Completion | 2025-02-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-10-09 with a primary completion date of 2025-02-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Post-COVID recovery is associated with reduced functional fitness/capacity, low quality of life, and physical disabilities in those who survived after contracting the disease. The unpleasant symptoms of chronic post-viral/post-COVID syndrome (chronic fatigue perception, variant nonspecific myalgia, bad mood or depression, and insomnia or sleep disturbances) usually magnify the symptoms of already existing previously diagnosed concurrent untreatable chronic disorders , including the idiopathic chronic fatigue (ICF).(Leszczak et al., 2024) Baduanjin exercise training (BET) is one of the Chinese traditional Health-Qigong exercises that not only integrate slow coordinating postures/positions, breathing techniques, musculoskeletal stretching movements/positions, and meditative mind but also plays a strong role concerning health benefits (e.g. musculoskeletal pain-reducing, sleep disturbance-enhancing effects, and fatigue-reducing effects) (Zou et al., 2018).
Eligibility Criteria
Inclusion Criteria: * • 40 patients will be recruited in the study. * age ≥ 18 to ≤ 50 years old * achieved three diagnostic items/criteria of ICF will be included in this BET trial: Fatigue lasting over 6 months, which significantly limits daily activities, reducing the person's usual activity level by more than 50%, as confirmed by a doctor. At least three of the following symptoms: Generalized muscle weakness Difficulty sleeping Frequent headaches A painful throat Muscle tenderness throughout the body Migratory joint pain Swollen lymph nodes in the neck or armpits Fatigue lasting more than a day after typical activities Exclusion Criteria: * Patients with a history of medical or complementary treatments for ICF disorder in the 6 months before contracting COVID or after recovery. * Individuals who have engaged in therapeutic exercise, pharmacological treatments, or complementary therapies for post-COVID symptoms within the last six months prior to enrollment. * ICF patients regularly using antidepressants or antipsychotics were excluded. * Those who take sleeping pills regularly were also excluded. * Patients with autoimmune diseases, malignant conditions, anemia, endocrine disorders, systemic diseases, or osteoarthritis affecting the cervical spine, lumbar region, or limbs were excluded. * Individuals with abnormal results in laboratory tests, including neurological, neurophysiological, cardiological, liver/kidney function tests, or urine/stool analyses (as determined by a physician) were excluded.
Contact & Investigator
Alaa El-moatasem, lecturer
PRINCIPAL INVESTIGATOR
Cairo University
Frequently Asked Questions
Who can join the NCT06829940 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Chronic COVID-19 Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06829940 currently recruiting?
Yes, NCT06829940 is actively recruiting participants. Contact the research team at alaamotasem@cu.edu.eg for enrollment information.
Where is the NCT06829940 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06829940 clinical trial?
NCT06829940 is sponsored by Cairo University. The principal investigator is Alaa El-moatasem, lecturer at Cairo University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.